Document ID: chunk:federal_register_of_legislation:F2019L01338:reg:9:p3
Version: federal_register_of_legislation:F2019L01338
Segment Type: reg
Provision Reference: reg 9 (pt 3/4)
Character Range: 9603–12404

or ureter, where that work began at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
             Note: working as a painter is defined in the Schedule 1 – Dictionary.
(12)      working as a hairdresser or barber for a cumulative period of at least 5 000 hours, before the clinical onset of malignant neoplasm of the renal pelvis or ureter, where that work began at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
            Note: working as a hairdresser or barber is defined in the Schedule 1 – Dictionary.
(13)      having renal stone disease of the affected urinary tract at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(14)      having hydronephrosis or hydroureter of the affected urinary tract at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(15)      having chronic renal failure at least one year before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
Note: chronic renal failure is defined in the Schedule 1 – Dictionary.
(16)      ingesting aristolochic acid as specified at least two years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
Note: ingesting aristolochic acid as specified is defined in the Schedule 1 – Dictionary.
(17)      consuming a total of at least 50 grams of phenacetin at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
Note: phenacetin is defined in the Schedule 1 – Dictionary.
(18)      being treated with systemic cyclophosphamide or systemic ifosfamide, at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(19)      being treated with chlornaphazine at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(20)      being treated with pioglitazone, or a medication containing pioglitazone, for a continuous period of at least one year, within the ten years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(21)      having diabetes mellitus for at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(22)      having an infection of the renal pelvis or ureter with Schistosoma haematobium at least five years before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(23)      having an indwelling ureteric stent or other foreign body in the ureter for a continuous period (excepting routine stent changes) of at least five years, before the clinical onset of malignant neoplasm of the renal pelvis or ureter;
(24)      having neurogenic bladder at least five years before the